NASDAQ:BIOL - Biolase Stock Price, Price Target & More

$0.34 +0.02 (+6.25 %)

(As of 04/23/2018 11:42 AM ET)

Previous Close$0.32

Today's Range$0.30 - $0.34

52-Week Range$0.28 - $1.45

Volume22,285 shs

Average Volume154,944 shs

Market Capitalization$33.26 million

P/E RatioN/A

Dividend YieldN/A

Beta1.72

About Biolase (NASDAQ:BIOL)

BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine in the United States and internationally. The company offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. Its dental imaging products comprise 3Shape Trios intraoral scanner and digital impression systems for high-speed digital 3-D picture taking; Galaxy BioMill CAD/CAM system that enables dental practitioners to design, scan, mill, and finish crowns, inlays, and veneers inside the dental office; and CEFLA NewTom VGi and VG3 3-D cone beam computed tomography devices. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Dental equipment & supplies

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:BIOL

CUSIPN/A

Webwww.biolase.com

Phone949-361-1200

Debt

Debt-to-Equity RatioN/A

Current Ratio2.70%

Quick Ratio1.78%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$46.93 million

Price / Sales0.74

Cash FlowN/A

Price / CashN/A

Book Value$0.29 per share

Price / Book1.17

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-16,850,000.00

Net Margins-35.91%

Return on Equity-67.04%

Return on Assets-39.50%

Miscellaneous

Employees195

Outstanding Shares102,350,000

How to Become a New Pot Stock Millionaire

Biolase (NASDAQ:BIOL) Frequently Asked Questions

What is Biolase's stock symbol?

Biolase trades on the NASDAQ under the ticker symbol "BIOL."

How were Biolase's earnings last quarter?

Biolase (NASDAQ:BIOL) posted its quarterly earnings results on Wednesday, March, 14th. The medical technology company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.04). The medical technology company earned $12.63 million during the quarter. Biolase had a negative net margin of 35.91% and a negative return on equity of 67.04%. View Biolase's Earnings History.

When is Biolase's next earnings date?

Biolase is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Biolase.

What price target have analysts set for BIOL?

1 Wall Street analysts have issued 12 month price objectives for Biolase's stock. Their predictions range from $2.50 to $2.50. On average, they expect Biolase's stock price to reach $2.50 in the next year. View Analyst Ratings for Biolase.

Who are some of Biolase's key competitors?

Some companies that are related to Biolase include Brainstorm Cell Therapeutics (BCLI), Sophiris Bio (SPHS), Axsome Therapeutics (AXSM), Vascular Biogenics (VBLT), Navidea Biopharmaceuticals (NAVB), Scynexis (SCYX), Vernalis (VNLPY), Obalon Therapeutics (OBLN), Neovasc (NVCN), Kromek Group (KMK), Acerus Pharmaceuti (TRLPF), Five Star Senior Living (FVE), BioSig Technologies (BSGM), Versartis (VSAR), Arcturus Therapeutics (ARCT), Pain Therapeutics (PTIE), Rexahn Pharmaceuticals (RNN) and Opiant Pharmaceuticals (OPNT).

Who are Biolase's key executives?

Biolase's management team includes the folowing people:

Mr. Harold C. Flynn Jr., CEO, Pres & Director (Age 53)
Mr. Dmitri Boutoussov Ph.D., VP of R&D (Age 55)
Mr. John R. Beaver, Sr. VP, CFO & Principal Accounting Officer (Age 57)
Mr. Richard R. Whipp, VP of Operations (Age 66)
Mr. William E. Brown Jr., VP of Bus. Devel. (Age 70)

Has Biolase been receiving favorable news coverage?

Media stories about BIOL stock have trended somewhat positive this week, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biolase earned a media sentiment score of 0.00 on Accern's scale. They also assigned news coverage about the medical technology company an impact score of 45.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Biolase?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biolase's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.34.

How big of a company is Biolase?

Biolase has a market capitalization of $33.26 million and generates $46.93 million in revenue each year. Biolase employs 195 workers across the globe.

How can I contact Biolase?

Biolase's mailing address is 4 CROMWELL, IRVINE CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]

MarketBeat Community Rating for Biolase (BIOL)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		151 (Vote Outperform)
Underperform Votes:		103 (Vote Underperform)
Total Votes:		254

MarketBeat's community ratings are surveys of what our community members think about Biolase and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Biolase (NASDAQ:BIOL) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Biolase in the last 12 months. Their average twelve-month price target is $2.50, suggesting that the stock has a possible upside of 635.29%. The high price target for BIOL is $2.50 and the low price target for BIOL is $2.50. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$2.50	$2.50	$2.50	$2.50
Price Target Upside:	635.29% upside	96.85% upside	96.85% upside	96.85% upside

Biolase (NASDAQ:BIOL) Consensus Price Target History

Price Target History for Biolase (NASDAQ:BIOL)

Biolase (NASDAQ:BIOL) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/25/2017	Singular Research	Initiated Coverage	Buy	$2.50	Low

(Data available from 4/23/2016 forward)

Biolase (NASDAQ:BIOL) Earnings History and Estimates Chart

Earnings by Quarter for Biolase (NASDAQ:BIOL)

Biolase (NASDAQ BIOL) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/1/2018		($0.04)					N/A
3/14/2018	Q4 2017	($0.04)	($0.04)		$12.63 million	View	Listen
11/1/2017	Q3 2017		($0.06)		$10.81 million	View	N/A
8/7/2017	Q2 2017	($0.02)	($0.06)		$12.61 million	View	Listen
5/3/2017	Q1 2017	($0.03)	($0.06)		$10.87 million	View	Listen
3/8/2017	Q4 2016	$0.02	($0.06)		$13.76 million	View	Listen
11/8/2016	Q316	($0.02)	($0.05)	$12.40 million	$13.20 million	View	Listen
8/1/2016	Q2 2016		($0.05)		$13.81 million	View	N/A
5/9/2016	Q116	($0.03)	($0.07)	$11.90 million	$11.00 million	View	N/A
3/9/2016	Q415	($0.09)	($0.04)	$13.90 million	$14.50 million	View	N/A
11/4/2015	Q315	($0.08)	($0.09)	$1.50 million	$11.20 million	View	N/A
8/5/2015	Q2 2015		($0.12)		$11.87 million	View	N/A
4/30/2015	Q1 2015		($0.09)		$10.86 million	View	N/A
3/4/2015	Q4 2014		($0.07)		$13.24 million	View	N/A
11/4/2014	Q314	($0.09)	($0.08)	$11.70 million	$12.70 million	View	N/A
8/7/2014	Q214	($0.08)	($0.17)	$12.97 million	$10.20 million	View	N/A
5/12/2014	Q114	($0.05)	($0.11)	$13.29 million	$11.50 million	View	N/A
3/5/2014	Q413	($0.04)	($0.04)	$15.67 million	$15.20 million	View	N/A
11/5/2013	Q313	($0.05)	($0.10)	$16.42 million	$12.30 million	View	N/A
8/7/2013	Q2 2013	($0.04)	($0.06)	$15.69 million	$14.20 million	View	Listen
5/7/2013	Q1 2013	($0.01)	($0.06)	$14.48 million	$14.60 million	View	N/A
3/6/2013	Q4 2012		$0.05	$18.03 million	$19.10 million	View	Listen
11/5/2012	Q3 2012		($0.02)			View	N/A
8/8/2012	Q2 2012		($0.06)			View	N/A
5/9/2012	Q1 2012		($0.05)			View	N/A
3/8/2012	Q4 2011	($0.03)	($0.06)			View	N/A
11/7/2011	Q3 2011	($0.01)	($0.03)			View	N/A
8/10/2011	Q2 2011	$0.04	($0.03)			View	N/A
5/9/2011	Q1 2011	$0.02	($0.02)			View	N/A
3/10/2011	Q4 2010	$0.01	$0.01			View	N/A
11/2/2010	Q3 2010	($0.08)	($0.10)			View	N/A
8/17/2010	Q2 2010	($0.11)	($0.16)			View	N/A
5/17/2010	Q1 2010	($0.08)	($0.20)			View	N/A
3/18/2010	Q4 2009	$0.09	($0.06)			View	N/A
11/5/2009	Q3 2009	$0.03	$0.05			View	N/A
8/6/2009	Q2 2009		$0.09			View	N/A
5/7/2009	Q1 2009		($0.18)			View	N/A
3/16/2009	Q4 2008	($0.06)	($0.19)			View	N/A
11/5/2008	Q3 2008	($0.06)	($0.17)			View	N/A
8/7/2008	Q2 2008	$0.01	$0.02			View	N/A
3/11/2008	Q4 2007	($0.01)	($0.01)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Biolase (NASDAQ:BIOL) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Biolase (NASDAQ BIOL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 36.18%

Insider Trading History for Biolase (NASDAQ:BIOL)

Institutional Ownership by Quarter for Biolase (NASDAQ:BIOL)

Biolase (NASDAQ BIOL) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2017	Larry N Feinberg	Major Shareholder	Buy	12,545,615	$0.43	$5,394,614.45
2/18/2016	Jack W Schuler	Major Shareholder	Buy	500	$0.80	$400.00
2/17/2016	Jack W Schuler	Major Shareholder	Buy	4,100	$0.80	$3,280.00
2/12/2016	Jack W Schuler	Major Shareholder	Buy	19,080	$0.76	$14,500.80
2/10/2016	Jack W Schuler	Major Shareholder	Buy	67,213	$0.78	$52,426.14
1/25/2016	Jack W Schuler	Major Shareholder	Buy	1,400	$0.80	$1,120.00
1/22/2016	Jack W Schuler	Major Shareholder	Buy	6,670	$0.78	$5,202.60
1/20/2016	Jack W Schuler	Major Shareholder	Buy	24,200	$0.75	$18,150.00
12/28/2015	Jack W Schuler	Major Shareholder	Buy	18,350	$0.79	$14,496.50
12/24/2015	Jack W Schuler	Major Shareholder	Buy	41,900	$0.76	$31,844.00
12/22/2015	Jack W Schuler	Major Shareholder	Buy	87,200	$0.74	$64,528.00
12/21/2015	Jack W Schuler	Major Shareholder	Buy	127,892	$0.73	$93,361.16
12/17/2015	Jack W Schuler	Major Shareholder	Buy	34,158	$0.70	$23,910.60
11/11/2015	Larry N Feinberg	Major Shareholder	Buy	54,800	$0.79	$43,292.00
11/10/2015	Paul N Clark	Director	Buy	134,579	$0.75	$100,934.25
9/24/2015	David C Dreyer	CFO	Buy	5,000	$1.20	$6,000.00	20,000
9/22/2015	David C Dreyer	CFO	Buy	5,000	$1.37	$6,850.00	15,000
9/17/2015	David C Dreyer	CFO	Buy	10,000	$1.45	$14,500.00	10,000
11/3/2014	Jeffrey M Nugent	CEO	Buy	40,465	$2.39	$96,711.35
11/3/2014	Jonathan T Md Lord	Director	Buy	101,163	$2.39	$241,779.57
11/3/2014	Larry N Feinberg	Major Shareholder	Buy	2,067,979	$2.39	$4,942,469.81
7/22/2014	Alexander K Arrow	COO	Buy	7,812	$1.92	$14,999.04
7/22/2014	Frederick D Furry	CFO	Buy	13,020	$1.92	$24,998.40
7/22/2014	Jeffrey M Nugent	CEO	Buy	52,083	$1.92	$99,999.36
7/22/2014	Paul N Clark	Director	Buy	520,833	$1.92	$999,999.36
7/18/2014	Larry N Feinberg	Major Shareholder	Buy	2,270,836	$1.92	$4,360,005.12
2/12/2014	Larry N Feinberg	Major Shareholder	Buy	2,035,033	$2.57	$5,230,034.81
1/31/2014	Larry Feinberg	major shareholder	Buy	30,798	$2.45	$75,455.10
12/19/2013	Larry Feinberg	major shareholder	Buy	340,000	$1.80	$612,000.00
12/17/2013	Larry Feinberg	major shareholder	Buy	150,400	$1.87	$281,248.00
8/23/2012	Frederick D Furry	CFO	Buy	5,075	$1.64	$8,323.00

(Data available from 1/1/2013 forward)

Biolase (NASDAQ BIOL) News Headlines

Source:

Date	Headline
	Contrasting Biolase (BIOL) & Sartorius (SARTF) www.americanbankingnews.com - April 19 at 9:08 PM
	Biolase (BIOL) & Straumann (SAUHF) Critical Review www.americanbankingnews.com - April 19 at 9:06 PM
	BIOLASE Establishes Southern California Dental Advisory Board finance.yahoo.com - April 17 at 9:56 AM
	Biolase (BIOL) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 16 at 7:35 PM
	Head-To-Head Analysis: Dentsply Sirona (XRAY) versus Biolase (BIOL) www.americanbankingnews.com - April 16 at 1:35 AM
	Head-To-Head Comparison: Biolase (BIOL) & Dentsply Sirona (XRAY) www.americanbankingnews.com - April 12 at 1:17 AM
	Sartorius (SARTF) vs. Biolase (BIOL) Head to Head Survey www.americanbankingnews.com - April 11 at 7:35 PM
	BIOLASE to explore strategic alternatives, CEO resigns seekingalpha.com - April 11 at 10:18 AM
	BRIEF-Biolase Has Asked Jonathan Lord Chairman Of Board Of Biolase, To Lead Co's Exploration Of Strategic Alternatives www.reuters.com - April 11 at 10:18 AM
	BIOLASE Board Of Directors Asks Chairman Jonathan T. Lord, M.D. To Take On Expanded Leadership Role And Explore Strategic Options finance.yahoo.com - April 11 at 10:18 AM
	Biolase (BIOL) Upgraded to Hold by ValuEngine www.americanbankingnews.com - April 8 at 1:29 PM
	Sartorius (SARTF) & BIOLASE (BIOL) Critical Survey www.americanbankingnews.com - April 5 at 10:11 AM
	BIOLASE Names Garrett Sato To Board Of Directors finance.yahoo.com - April 4 at 5:11 PM
	BIOLASE Announces Growing Awareness of Dental Lasers Among Pediatric Dentists, Demonstrating Shift Toward Pain-Free Dentistry finance.yahoo.com - March 28 at 9:53 AM
	Head-To-Head Comparison: Henry Schein (HSIC) & BIOLASE (BIOL) www.americanbankingnews.com - March 26 at 11:27 PM
	Edited Transcript of BIOL earnings conference call or presentation 14-Mar-18 8:30pm GMT finance.yahoo.com - March 18 at 9:32 AM
	BIOLASE (BIOL) Releases Quarterly Earnings Results, Hits Expectations www.americanbankingnews.com - March 15 at 7:56 AM
	BIOLASE, Inc. to Host Earnings Call www.baystreet.ca - March 14 at 5:31 PM
	BIOLASE Reports 2017 Fourth Quarter And Full-Year Results www.bizjournals.com - March 14 at 5:31 PM
	Is It Too Late To Buy BIOLASE Inc (NASDAQ:BIOL)? finance.yahoo.com - March 14 at 10:42 AM
	BIOLASE (BIOL) Set to Announce Earnings on Wednesday www.americanbankingnews.com - March 7 at 8:20 PM
	BIOLASE Secures $6 Million Revolving Line Of Credit finance.yahoo.com - March 7 at 9:44 AM
	BIOLASE® To Host 2017 Fourth Quarter Financial Results Conference Call On March 14, 2018 finance.yahoo.com - March 6 at 9:28 AM
	Biolase (BIOL) Announces MOU With S-Ray to Market, Sell Disruptive Radiation-Free Dental Imaging Device www.streetinsider.com - February 28 at 9:32 AM
	BIOLASE Announces Memorandum Of Understanding With S-Ray To Market, Sell Disruptive Radiation-Free Dental Imaging Device finance.yahoo.com - February 27 at 9:37 AM
	BIOLASE (BIOL) Set to Announce Earnings on Tuesday www.americanbankingnews.com - February 27 at 2:16 AM
	Dynatronics (DYNT) Reports Separation of Chairmanship and CEO Positions; Chairman and CEO Kelvyn Cullimore to Step Down www.streetinsider.com - February 23 at 4:47 PM
	BIOLASE Announces Initiatives to Increase Dental Laser Awareness and Education in Southern California finance.yahoo.com - February 15 at 8:51 AM
	Nasdaq Grants BIOLASE 180-Day Extension To Meet Minimum Bid Price Requirement finance.yahoo.com - February 7 at 9:06 AM
	BRIEF-CAO Group Filed Patent Infringement Lawsuits In Court Against Biolase www.reuters.com - January 24 at 4:52 PM
	CAO Group, Inc. Protects Its Diode Laser Patent Rights From Infringement By Biolase, Inc. finance.yahoo.com - January 24 at 4:52 PM
	BRIEF-Biolase Files For Possible Resale Of Up To 21.9 Mln Shares Of Common Stock By Selling Stockholders www.reuters.com - January 16 at 5:38 PM
	BIOLASE Receives Awards From Leading Industry Organizations ... - PR Newswire (press release) www.prnewswire.com - January 5 at 3:47 PM
	BIOLASE Receives Awards From Leading Industry Organizations For Its Dental Laser Systems finance.yahoo.com - January 4 at 9:05 AM
	Critical Contrast: Biolase (BIOL) & ArthroCare (ARTC) www.americanbankingnews.com - December 22 at 3:04 AM
	ETFs with exposure to BIOLASE, Inc. : December 11, 2017 finance.yahoo.com - December 11 at 3:43 PM
	Critical Analysis: Mindray Medical International (MR) versus Biolase (BIOL) www.americanbankingnews.com - December 7 at 3:32 AM
	Biolase, Inc. (BIOL) Major Shareholder Larry N. Feinberg Purchases 12,545,615 Shares www.americanbankingnews.com - December 6 at 5:22 PM
	Zacks: Biolase, Inc. (BIOL) Given Average Rating of "Strong Buy" by Analysts www.americanbankingnews.com - December 2 at 11:30 PM
	ETFs with exposure to BIOLASE, Inc. : December 1, 2017 finance.yahoo.com - December 1 at 4:27 PM
	BRIEF-BIOLASE Announces Expiration Of Rights Offering www.reuters.com - November 30 at 3:44 PM
	BIOLASE Announces Expiration of Rights Offering finance.yahoo.com - November 30 at 9:12 AM
	Financial Comparison: Biolase (BIOL) and Synergetics USA (SURG) www.americanbankingnews.com - November 28 at 1:08 AM
	BIOLASE to Conduct Demos of Portable Waterlase Express™ All-Tissue Laser System at Greater New York Dental Meeting finance.yahoo.com - November 22 at 5:15 PM
	ETFs with exposure to BIOLASE, Inc. : November 20, 2017 finance.yahoo.com - November 20 at 3:23 PM
	BIOLASE to Present at the LD Micro 10th Annual Main Event Conference finance.yahoo.com - November 17 at 8:42 AM
	BIOLASE to Present at the Singular Research Best of the Uncovered 12th Annual Conference 2017 finance.yahoo.com - November 16 at 9:33 AM
	Biolase (BIOL) Commences Rights Offering www.streetinsider.com - November 11 at 4:25 PM
	BIOLASE Announces Commencement of Rights Offering finance.yahoo.com - November 9 at 5:41 PM
	ETFs with exposure to BIOLASE, Inc. : November 9, 2017 finance.yahoo.com - November 9 at 5:41 PM

Biolase (NASDAQ:BIOL) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Biolase (NASDAQ:BIOL) Income Statement, Balance Sheet and Cash Flow Statement

Biolase (NASDAQ BIOL) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff